{"id":"nt0102","safety":{"commonSideEffects":[{"rate":null,"effect":"Decreased appetite"},{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Anxiety"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"NT0102 utilizes Neos Therapeutics' proprietary technology to deliver methylphenidate in a controlled manner that aims to minimize peak plasma concentrations and reduce the drug's potential for misuse. The formulation is engineered to provide therapeutic benefit for ADHD while maintaining a lower abuse liability profile compared to immediate-release methylphenidate formulations.","oneSentence":"NT0102 is a prodrug formulation of methylphenidate designed to provide extended-release delivery with reduced abuse potential.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:23:27.365Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Attention-deficit/hyperactivity disorder (ADHD) in children and adolescents"}]},"trialDetails":[{"nctId":"NCT01835548","phase":"PHASE3","title":"NT0102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"Neos Therapeutics, Inc","startDate":"2013-07","conditions":"Attention Deficit Hyperactivity Disorder (ADHD)","enrollment":87}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"NT0102","genericName":"NT0102","companyName":"Neos Therapeutics, Inc","companyId":"neos-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"NT0102 is a prodrug formulation of methylphenidate designed to provide extended-release delivery with reduced abuse potential. Used for Attention-deficit/hyperactivity disorder (ADHD) in children and adolescents.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}